Selected research
Industry Research
Amyloidosis Therapeutics Industry Research Report 2026
Market perspective
The global Amyloidosis Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Amyloidosis Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Amyloidosis Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Amyloidosis Therapeutics include Pfizer Inc., GlaxoSmithKline Plc, SOM Innovation Biotech SL, Prothena Corporation Plc, ProteoTech, Inc., Onyx Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and Celgene Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Amyloidosis Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Amyloidosis Therapeutics Market by Company
Pfizer Inc.
GlaxoSmithKline Plc
SOM Innovation Biotech SL
Prothena Corporation Plc
ProteoTech, Inc.
Onyx Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Celgene Corporation
Bsim2
Bellus Health Inc.
Arcturus Therapeutics, Inc
Alnylam Pharmaceuticals, Inc.
Amyloidosis Therapeutics Segment by Type
Canakinumab
CAEL-101
ALN-TTRsc02
ALN-ANG
AG-10
Others
Amyloidosis Therapeutics Segment by Application
ATTR Amyloidoses
AL Amyloidosis
AA Amyloidoses
Others
Amyloidosis Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyloidosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Amyloidosis Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Amyloidosis Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Amyloidosis Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Canakinumab
- CAEL-101
- ALN-TTRsc02
- ALN-ANG
- AG-10
- Others
Applications
- ATTR Amyloidoses
- AL Amyloidosis
- AA Amyloidoses
- Others
Companies covered
- Pfizer Inc.
- GlaxoSmithKline Plc
- SOM Innovation Biotech SL
- Prothena Corporation Plc
- ProteoTech, Inc.
- Onyx Pharmaceuticals, Inc.
- Millennium Pharmaceuticals, Inc.
- Isis Pharmaceuticals, Inc.
- Celgene Corporation
- Bsim2
- Bellus Health Inc.
- Arcturus Therapeutics, Inc
- Alnylam Pharmaceuticals, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Amyloidosis Therapeutics Market Size (2021-2032)
- 2.2.2 Global Amyloidosis Therapeutics Sales (2021-2032)
- 2.2.3 Global Amyloidosis Therapeutics Market Average Price (2021-2032)
- 2.3 Amyloidosis Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Canakinumab
- 2.3.3 CAEL-101
- 2.3.4 ALN-TTRsc02
- 2.3.5 ALN-ANG
- 2.3.6 AG-10
- 2.3.7 Others
- 2.4 Amyloidosis Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 ATTR Amyloidoses
- 2.4.3 AL Amyloidosis
- 2.4.4 AA Amyloidoses
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Amyloidosis Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Amyloidosis Therapeutics Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Amyloidosis Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Amyloidosis Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Amyloidosis Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Amyloidosis Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Amyloidosis Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Amyloidosis Therapeutics, Established Date
- 3.9 Global Amyloidosis Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer Inc.
- 4.1.1 Pfizer Inc. Company Information
- 4.1.2 Pfizer Inc. Business Overview
- 4.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Inc. Amyloidosis Therapeutics Product Portfolio
- 4.1.5 Pfizer Inc. Recent Developments
- 4.2 GlaxoSmithKline Plc
- 4.2.1 GlaxoSmithKline Plc Company Information
- 4.2.2 GlaxoSmithKline Plc Business Overview
- 4.2.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio
- 4.2.5 GlaxoSmithKline Plc Recent Developments
- 4.3 SOM Innovation Biotech SL
- 4.3.1 SOM Innovation Biotech SL Company Information
- 4.3.2 SOM Innovation Biotech SL Business Overview
- 4.3.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio
- 4.3.5 SOM Innovation Biotech SL Recent Developments
- 4.4 Prothena Corporation Plc
- 4.4.1 Prothena Corporation Plc Company Information
- 4.4.2 Prothena Corporation Plc Business Overview
- 4.4.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio
- 4.4.5 Prothena Corporation Plc Recent Developments
- 4.5 ProteoTech, Inc.
- 4.5.1 ProteoTech, Inc. Company Information
- 4.5.2 ProteoTech, Inc. Business Overview
- 4.5.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio
- 4.5.5 ProteoTech, Inc. Recent Developments
- 4.6 Onyx Pharmaceuticals, Inc.
- 4.6.1 Onyx Pharmaceuticals, Inc. Company Information
- 4.6.2 Onyx Pharmaceuticals, Inc. Business Overview
- 4.6.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
- 4.6.5 Onyx Pharmaceuticals, Inc. Recent Developments
- 4.7 Millennium Pharmaceuticals, Inc.
- 4.7.1 Millennium Pharmaceuticals, Inc. Company Information
- 4.7.2 Millennium Pharmaceuticals, Inc. Business Overview
- 4.7.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
- 4.7.5 Millennium Pharmaceuticals, Inc. Recent Developments
- 4.8 Isis Pharmaceuticals, Inc.
- 4.8.1 Isis Pharmaceuticals, Inc. Company Information
- 4.8.2 Isis Pharmaceuticals, Inc. Business Overview
- 4.8.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
- 4.8.5 Isis Pharmaceuticals, Inc. Recent Developments
- 4.9 Celgene Corporation
- 4.9.1 Celgene Corporation Company Information
- 4.9.2 Celgene Corporation Business Overview
- 4.9.3 Celgene Corporation Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Celgene Corporation Amyloidosis Therapeutics Product Portfolio
- 4.9.5 Celgene Corporation Recent Developments
- 4.10 Bsim2
- 4.10.1 Bsim2 Company Information
- 4.10.2 Bsim2 Business Overview
- 4.10.3 Bsim2 Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bsim2 Amyloidosis Therapeutics Product Portfolio
- 4.10.5 Bsim2 Recent Developments
- 4.11 Bellus Health Inc.
- 4.11.1 Bellus Health Inc. Company Information
- 4.11.2 Bellus Health Inc. Business Overview
- 4.11.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio
- 4.11.5 Bellus Health Inc. Recent Developments
- 4.12 Arcturus Therapeutics, Inc
- 4.12.1 Arcturus Therapeutics, Inc Company Information
- 4.12.2 Arcturus Therapeutics, Inc Business Overview
- 4.12.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio
- 4.12.5 Arcturus Therapeutics, Inc Recent Developments
- 4.13 Alnylam Pharmaceuticals, Inc.
- 4.13.1 Alnylam Pharmaceuticals, Inc. Company Information
- 4.13.2 Alnylam Pharmaceuticals, Inc. Business Overview
- 4.13.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
- 4.13.5 Alnylam Pharmaceuticals, Inc. Recent Developments
5 Global Amyloidosis Therapeutics Market Scenario by Region
- 5.1 Global Amyloidosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Amyloidosis Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Amyloidosis Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Amyloidosis Therapeutics Sales by Region: 2027-2032
- 5.3 Global Amyloidosis Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Amyloidosis Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Amyloidosis Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Amyloidosis Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Amyloidosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Amyloidosis Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Amyloidosis Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Amyloidosis Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Amyloidosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Amyloidosis Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Amyloidosis Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Amyloidosis Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Amyloidosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Amyloidosis Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Amyloidosis Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Amyloidosis Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Amyloidosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Amyloidosis Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Amyloidosis Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Amyloidosis Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Amyloidosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Amyloidosis Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Amyloidosis Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Amyloidosis Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Amyloidosis Therapeutics Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Amyloidosis Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Amyloidosis Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Amyloidosis Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Amyloidosis Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Amyloidosis Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Amyloidosis Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Amyloidosis Therapeutics Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Amyloidosis Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Amyloidosis Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Amyloidosis Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Amyloidosis Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Amyloidosis Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Amyloidosis Therapeutics Value Chain Analysis
- 8.1.1 Amyloidosis Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Amyloidosis Therapeutics Production Mode & Process
- 8.2 Amyloidosis Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Amyloidosis Therapeutics Distributors
- 8.2.3 Amyloidosis Therapeutics Customers
9 Global Amyloidosis Therapeutics Analyzing Market Dynamics
- 9.1 Amyloidosis Therapeutics Industry Trends
- 9.2 Amyloidosis Therapeutics Industry Drivers
- 9.3 Amyloidosis Therapeutics Industry Opportunities and Challenges
- 9.4 Amyloidosis Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst